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Construction of a herpes simplex virus 2 (HSV-2) bacterial artificial chromosome (BAC) is described. BAC vector sequences were
inserted into the thymidine kinase gene of HSV-2 by homologous recombination. DNA from cells infected with the resulting recombinant
virus was transformed into E. coli, and colonies containing the HSV-2 BAC (HSV2-BAC) were isolated and analyzed for the expected
genotype. HSV2-BAC DNA was infectious when transfected back into mammalian cells and the resulting virus was thymidine kinase
negative. When used to immunize mice, the HSV2-BAC DNA elicited a strong HSV-2 specific antibody response that was equal to or greater
than live virus immunization. Further, HSV2-BAC immunization was protective when animals were challenged with a lethal dose of virus.
The utility of the HSV2-BAC for construction of recombinant virus genomes was demonstrated by elimination of the HSV-2 glycoprotein D
(gD) gene. A recombinant HSV-2 BAC with the gD gene deleted was isolated and shown to be incapable of producing infectious virus
following transfection unless an HSV gD gene was expressed in a complementing cell line. Immunization of mice with the HSV2 gD-BAC
also elicited an HSV-2 specific antibody response and was protective. The results demonstrate the feasibility of DNA immunization with
HSV-2 bacterial artificial chromosomes for replicating and nonreplicating candidate HSV-2 vaccines, as well as the utility of BAC
technology for construction and maintenance of novel HSV-2 vaccines. The results further suggest that such technology will be a powerful
tool for dissecting the immune response to HSV-2.
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IntroductionSeveral large DNA and RNA viruses have been cloned as
bacterial artificial chromosomes (BACs), including poxvi-
ruses (Domi and Moss, 2002), herpesviruses [e.g., Epstein-
Barr virus, (Delecluse et al., 1998), human and mouse
cytomegaloviruses (Borst et al., 1999; Messerle et al.,
1997), pseudorabies virus (Smith and Enquist, 2000), herpes
simplex virus 1 (Horsburgh et al., 1999b; Saeki et al., 1998;
Stavropoulos and Strathdee, 1998)], and coronaviruses [e.g.,
transmissible gastroenteritis (Almazan et al., 2000)]. A
major utility of constructing such recombinant viral BACs
is the resulting ease with which the viral genome can be0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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E-mail address: weirj@cber.fda.gov (J.P. Weir).manipulated with prokaryotic genetic techniques to con-
struct recombinant viruses. For example, essential and
nonessential virus genes can be rapidly identified without
construction of complementing cell lines (Brune et al.,
1999). Furthermore, because all manipulations are per-
formed as DNA clones in a prokaryotic system, the chance
of isolating a recombinant genome with unrelated mutations
should be reduced. Since the mutated genome exists as a
DNA clone, sequence analysis of recombinants is facilitated
and plaque purification of the resulting recombinant virus is
not required.
Viral BACs could also be potentially used for immuni-
zation. In theory, a BAC containing the entire genome of a
nonreplicating virus could be used to deliver almost the
entire spectrum of viral genes as a DNA vaccine. Such an
approach using a nonreplicating HSV-1 BAC has recently
been described (Suter et al., 1999). However, the future of
DNA vaccines is still not clear. While DNA vaccines have
shown promise in animal studies, their utility in humans is
yet to be proven. Nevertheless, DNA vaccines, particularly
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mune response that mimics natural infection, may have a
role in new generation vaccines, possibly as part of novel
prime-boost combinations using other vectors.
In addition to delivery of nonreplicating viral genomes,
BACs could also be used to deliver the genome of a
replicating virus for live virus immunization. Most of the
advantages (e.g., good immunogenicity and stimulation of
humoral and cellular immunity) and disadvantages (e.g.,
safety concerns and potential virus latency or persistence) of
live virus vaccines are well known. Maintenance of live
virus vaccines as DNA in the form of a BAC would offer
additional advantages to the generation and production of
live virus vaccines. A major advantage, as noted above, is
that construction of new-generation virus vaccines would be
facilitated. In addition, viral vaccine stocks could be re-
derived as necessary by transfection of BAC DNA into new
qualified cell lines, thus eliminating concerns regarding
potential contamination or undocumented virus seed history.
Finally, if viral vaccines could be produced and delivered as
DNA, concerns about the cell substrates used for vaccine
production, including tumorigenicity and the presence of
unknown adventitious agents, could be eliminated.
Here, we describe the construction of a herpes simplex
virus 2 (HSV-2) BAC and evaluate the ability of this DNA
construction to immunize mice and protect them against a
lethal challenge of HSV-2. We demonstrate the utility of this
HSV-2 BAC system for construction of new genomes by
engineering a nonreplicating glycoprotein D (gD)-negativeFig. 1. Schematic diagram of the structure of HSV2-BAC. The BeloBAC vec
homologous recombination between HSV-2 and the insertion vector pSP72tkBeloB
the HindIII site used for insertion into the tk gene of pSP72tkBeloBAC.HSV-2. Finally, we show that DNA immunization with the
gD-negative BAC DNA also elicits a protective immune
response. Thus, BAC technology provides a mechanism to
dissect and characterize the contribution of individual viral
genes to the generation of protective immunity.Results
Construction and characterization of a herpes simplex virus
2 bacterial artificial chromosome
To clone the HSV-2 genome as a bacterial artificial
chromosome, we constructed a plasmid insertion vector to
insert the E. coli F-factor replicon into the viral genome.
This insertion plasmid, designated as pSP72tk2-BeloBAC
(Fig. 1), contains the 7.5-kb BeloBAC11 sequence which
includes the F-factor origin of replication, the choramphe-
nicol acetyltransferase (cat) gene, and the regulatory genes
necessary for replication and maintenance at a low copy
number in its E. coli host. In addition, the BeloBAC11
sequence is flanked by two approximately 1.75-kb frag-
ments of HSV-2 sequence around the thymidine kinase (tk)
gene which are designed to target the BeloBAC sequence to
the HSV-2 tk locus for insertion during homologous recom-
bination. Recombinant HSV-2 was generated by co-trans-
fection of pSP72tk2-BeloBAC and HSV-2 genomic DNA
into Vero cells, followed by selection for thymidine kinase
negative virus in the presence of acyclovir.tor sequences were inserted into the HSV-2 thymidine kinase gene via
AC. The single XhoI restriction site in BeloBAC is approximately 2 kb from
Fig. 3. Virus replication analysis of HSV-2 and HSV2-BAC virus. Vero cells
(5  105) were infected with HSV-2 or HSV2-BAC virus at an moi of 0.1 in
the presence or absence of acyclovir. Total virus yields at the indicated times
postinfection were determined by plaque assay on Vero cells.
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phenicol gene were identified and re-plaqued one time
before preparation of infected cell DNA which was used
to transform E. coli DH10B. Chloramphenicol-resistant
colonies obtained from each of the two original virus
recombinants were selected and analyzed for the presence
of BeloBAC and HSV-2 sequences. HSV2-BAC DNA from
two independent clones, derived from the two independent
virus recombinants, was analyzed by restriction enzyme
analysis and Southern blotting to verify the structure of
the HSV2-BAC and the insertion of the BeloBAC11
sequences into the thymidine kinase (tk) gene (Fig. 2).
The tk gene is located within a 6164-bp XhoI fragment
(coordinates 45174–51311; GenBank accession number ,
Z86099) (Fig. 2A, lane 2). Insertion of the 7400-bp Belo-
BAC sequence (containing a single XhoI site) followed by
digest with XhoI results in tk- and BeloBAC-positive frag-
ments of approximately 4300 and 9200 bp (Figs. 2A and B,
lanes 1 and 3). DNA from each HSV2-BAC isolate was
infectious when transfected into Vero cells; approximately
105 plaque-forming units (pfu) of virus were produced by
transfection of 1 Ag of HSV2-BAC DNA (data not shown).
Virus derived from HSV2-BAC DNA replicated to slightly
lower levels than wild-type HSV-2 in Vero cells; HSV2-
BAC virus was thymidine kinase deficient as expected, as
shown by its ability to replicate in the presence of acyclovir
(Fig. 3).
Immunization with an HSV-2 BAC
To determine the feasibility of immunization using DNA
from the HSV2-BAC, we delivered HSV2-BAC DNA by
gene gun and compared the immune response to live virus
immunization. Four groups of mice were immunized withFig. 2. Southern blot analysis of HSV2-BAC. The DNA from two independently
XhoI restriction digest and Southern blotting. HSV-2 DNA (lane 2) and HSV2-BAC
51311) thymidine kinase sequence probe (A) or a BeloBAC vector probe (B) to co
markers (M) are indicated in kilobase pairs to the left of each figure.either 1 Ag of HSV2-BAC DNA, 5  104 pfu of HSV2-
BAC virus, 5  102 pfu of HSV2-BAC virus, or 1 Ag of
control DNA (pBeloBAC). Serum samples were obtained 3
weeks later and analyzed for the presence of HSV-2 specific
antibody (Fig. 4A). A single inoculation with 1 g of HSV2-
BAC DNA resulted in a readily detectable HSV-2 specific
IgG response in all animals, as did inoculation with 5  104
pfu of virus. Only two of five animals inoculated one time
with the lower dose of virus responded with detectable
HSV-2 specific IgG. Three weeks after immunization, each
group of animals was boosted with the same dose of DNA
or virus as received in the first immunization; sera were
again collected 3 weeks later. After the second immuniza-
tion with either DNA or virus, all mice in each vaccinatedisolated bacterial clones containing the HSV2-BAC DNA was analyzed by
DNA (lanes 1 and 3) were hybridized with a 3.47-kb (coordinates 45174–
nfirm the correct site of insertion of BeloBAC sequences. The size of DNA
Fig. 4. Antibody response following immunization with HSV2-BAC DNA.
Mice were immunized two times with 1 Ag of HSV2-BAC DNA, 5  104
pfu of HSV2-BAC virus, 5  102 pfu of HSV2-BAC virus, or 1 Ag of
pBeloBAC control DNA. Results from a representative experiment, of two
experiments of similar design and outcome, are shown. Each group
consisted of five animals. (A) HSV-2 specific IgG was determined for
individual mice 3 weeks following the first immunization and 3 weeks
following a booster immunization with the same dose of either DNA or
virus. The number of mice with a detectable IgG titer (z1:20) is indicated if
less than five. Calculation of the mean IgG titer includes a value of 1:10 for
sero-negative animals. (B) The titer of HSV-2 specific IgG isotypes was
determined 3 weeks after 2 immunizations with 1 Ag of HSV2-BAC DNA
(DNA) and 5  104 pfu of HSV2-BAC virus (virus). The number of mice
with a detectable antibody titer (z1:40) is indicated if less than five.
Calculation of the mean IgG titer includes a value of 1:20 for sero-negative
animals.
Fig. 5. Lethal challenge of HSV2-BAC DNA- and HSV2-BAC virus-
immunized mice. Three weeks following the booster immunization with
HSV2-BAC DNA, HSV2-BAC virus, or control DNA, mice were
challenged intraperitoneally with 5  106 pfu (approximately 25 LD50)
of HSV-2 (MS). Survival curves are shown for each group of animals.
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in each group was observed. There was a relatively large
variability in the specific HSV-2 antibody response in the
group receiving the lower dose of HSV2-BAC virus, likely
reflecting the poor initial response in three of the five
animals. Further analysis of the sera obtained after twoimmunizations with either HSV2-BAC DNA or 5  104
pfu of HSV2-BAC virus revealed high titers of IgG1, IgG2a,
and IgG2b in both groups, indicating a broad humoral
immune response to both types of immunization (Fig. 4B).
HSV-2 specific IgG3 was detectable in all five animals in the
HSV2-BAC DNA-immunized group, but in only two of the
five animals in the virus-immunized group. In addition, sera
obtained after two immunizations with either HSV2-BAC
DNA or 5  104 pfu of HSV2-BAC virus were capable of
neutralizing HSV-2 in vitro [3.06F 0.30 and 2.11F 0.51
(P = 0.007), mean 50% neutralization titers (log 10),
respectively]. Finally, mice immunized with HSV2-BAC
DNA survived a lethal challenge of HSV-2 (five of five)
as did 80% (four of five; P = 1.00) of the animals receiving
the higher dose of HSV2-BAC virus (Fig. 5). In the
experiment shown in Fig. 5, three of five animals in the
group receiving the lower dose and one mouse in the group
receiving the higher dose of HSV2-BAC virus succumbed to
virus challenge. These animals had the lowest HSV-specific
IgG antibody levels after two immunizations in their respec-
tive groups (data not shown). The three animals in the low-
dose group were the same animals without a detectable HSV
antibody after one immunization, suggesting a rough corre-
lation between antibody response and protection against
lethal challenge. Taken together, these analyses indicated
that gene gun delivery of HSV2-BAC DNA elicited strong
HSV-specific antibody responses and substantial protection
against lethal challenge, equivalent to or greater than live
virus immunization.
Construction of recombinant HSV-2 bacterial artificial
chromosomes
One of the major advantages of cloning a large virus
such as HSV-2 as a bacterial artificial chromosome is the
Fig. 7. Lethal challenge of HSV2-BAC DNA- and HSV2 gD-BAC DNA-
immunized mice. Three weeks following the booster immunization with
HSV2-BAC DNA, HSV2 gD-BAC DNA, or control DNA, mice were
challenged intraperitoneally with 2  106 pfu (approximately 10 LD50) of
HSV-2 (MS). Survival curves are shown for each group of animals.
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Such recombinant HSV-2 genomes might find use as
newer generation live virus vaccines. We investigated
the ease of HSV2-BAC manipulation by constructing a
replication-incompetent genome that was missing the
essential glycoprotein D gene. This allowed us to deter-
mine the feasibility of BAC immunization with a repli-
cation-incompetent HSV-2 virus, and also investigate the
immunogenicity of HSV-2 in the absence of one of the
major immunodominant viral antigens. For deletion of the
HSV-2 gene, we constructed a gene replacement plasmid
vector which contained approximately 2 kb of DNA
sequences upstream of the gD-coding region linked to
approximately 2 kb of sequences immediately downstream
of the gD-coding region. The gD sequences target the
vector to the gD region of the HSV2-BAC for deletion of
the gD-coding region. In addition, the replacement vector
contains a temperature-sensitive origin of replication and
marker genes for positive and negative selection during
the BAC mutagenesis procedure as described previously
(Horsburgh et al., 1999a, 1999b). The absence of the gD
gene in the mutagenized HSV2-BAC was confirmed by
PCR analysis (see Materials and methods). The resulting
HSV2 gD-BAC was not infectious when the DNA was
transfected into Vero cells (<4 pfu/ml per gram of trans-
fected DNA), but was infectious when transfected into a
Vero cell line (VD60) that expresses HSV-1 gD (data not
shown). These results verified the genotype and the
resulting phenotype of the replication-incompetent HSV2
gD-BAC.Fig. 6. Antibody response following immunization with HSV2-BAC and
HSV2 gD-BAC DNA. Mice were immunized with 1 Ag of pBeloBAC
control DNA, HSV2-BAC DNA, or HSV2 gD-BAC DNA. Serum samples
were collected and analyzed for HSV-2 specific IgG at 3 weeks after the
first immunization and 3 weeks following a booster immunization of the
same dose of DNA at 3 weeks. Results from a representative experiment, of
2 experiments of similar design and outcome, are shown.Immunization with HSV2 DgD-BAC
Although missing one of the major immunodominant
HSV2 gD-BAC DNA HSV-2 glycoproteins, it was of
obvious interest to determine the ability of HSV2 gD-BAC
DNA to elicit an immune response in immunized animals.
Mice were immunized two times at 3-week intervals by gene
gun inoculation with 1 Ag of control DNA (pBeloBAC
vector), HSV2-BAC DNA, or HSV2 gD-BAC DNA. HSV-
2 specific IgG antibody was detected following each immu-
nization with both HSV2-BAC and HSV2 gD-BAC DNA
(Fig. 6), and sera obtained after two immunizations with
either HSV2-BAC or HSV2 gD-BAC DNAwere capable of
neutralizing HSV-2 infectivity in vitro [2.29F 0.59 and
1.75F 0.25 (P = 0.096), mean 50% neutralization titers
(log 10), respectively]. Furthermore, mice immunized with
either HSV2-BAC DNA or HSV2 gD-BAC DNA survived a
lethal challenge with HSV-2 (Fig. 7).
Discussion
The recent reports that herpesvirus genomes can be
cloned and maintained as bacterial artificial chromosomes
has facilitated genetic studies of these large DNA virus
genomes (reviewed recently in Wagner et al., 2002). The
potential applications are numerous and include basic stud-
ies of viral pathogenesis, gene identification and character-
ization, and the development of new viral vectors and
vaccines. Effective vaccines are not available for herpes
simplex virus 2, the principal causative agent of genital
herpes. Furthermore, it is not certain whether a successful
vaccine against HSV-2 can be developed, nor is it clear what
type of vaccine approach (e.g., live attenuated, subunit,
DNA) is most likely to be successful. With these consid-
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ogy could be beneficial for multiple types of HSV-2 vaccine
studies, including construction of attenuated virus strains,
DNA vaccine evaluation, and the characterization of the
contribution of individual viral genes to the generation of
protective immunity.
To construct an HSV-2 bacterial artificial chromosome,
we followed a procedure similar to that described for
construction of an HSV-1 BAC (Horsburgh et al., 1999b).
Insertion of the BeloBAC11 sequence into the HSV-2
thymidine kinase gene allowed for selection of the recom-
binant virus in the presence of acyclovir, followed by
isolation of circular DNA that could be recovered by
bacterial transformation. This procedure resulted in an
HSV-2 with a thymidine kinase negative phenotype. While
thymidine kinase is necessary for viral virulence and thus
important for viral pathogenesis studies, it is also a target of
antiviral drugs such as acyclovir or ganciclovir and thus
would be an important safety feature in any live attenuated
herpesvirus vaccine. The HSV2-BAC constructed in the
present study is not envisioned as a vaccine for HSV-2 per
se, but rather is used to demonstrate the feasibility of HSV-2
BAC immunization and the utility of an HSV-2 BAC for
further manipulation of the viral genome. Before any HSV
vaccine can be effectively evaluated as a vaccine, a thor-
ough characterization of its ability to induce cellular as well
as humoral immunity would be necessary, and its protective
capabilities in multiple relevant animal models would need
to be assessed. In addition, any live HSV-2 virus considered
for use as a vaccine would require a demonstrated attenu-
ated phenotype, extensive characterization of the BAC
genome including sequence analysis of the genomic termini,
reduced or impaired ability to establish and be reactivated
from latency, and a functional thymidine kinase gene (for
safety reasons). Such targeted manipulations of the viral
genome to confer attenuation and impair reactivation from
latency could easily be incorporated into a candidate vac-
cine through BAC mutagenesis for preclinical studies; a
thymidine kinase negative BAC virus could be repaired by
insertion of an intact thymidine kinase gene at another
location in the genome in a relatively straightforward
procedure. There have been recent reports that describe
alternative sites for insertion of the BAC vector sequences
including the intergenic region between the UL3 and UL4
genes of HSV-1 (Tanaka et al., 2003). In addition, methods
have been described that allow the removal of BAC vector
sequences from herpesvirus BACs (Smith and Enquist,
2000; Tanaka et al., 2003; Wagner et al., 1999). Clearly,
the availability of full-length infectious clones of herpesvi-
ruses such as HSV-2, and the techniques for their manipu-
lation, provide powerful tools for the development of new
generation vaccines.
One of the major goals of the studies reported here was to
determine the feasibility of immunization with HSV2-BAC
DNA. Two immunizations with 1 Ag of HSV2-BAC DNA
by gene gun inoculation into mice resulted in a robust HSV-specific IgG antibody response and neutralizing antibody
response. We observed some variation in the absolute
antibody titer between experiments (e.g., the antibody titer
elicited by HSV2-BAC DNA immunization presented in
Figs. 4 and 6), which was most likely due to the particular
preparation of BAC DNA used for delivery in the experi-
ment. Nevertheless, the HSV-specific antibody response
following HSV2-BAC immunization was reproducibly high
and the response was consistent in that every animal in five
independent experiments responded with detectable anti-
body (data not shown).
The choice of 1 Ag of BAC DNA for delivery by gene
gun was arbitrary, but based on considerations of practical-
ity (e.g., relatively small amounts of BAC DNA) and the
amount of infectious virus produced from HSV2-BAC
DNA. While we did not formally demonstrate that the
HSV2-BAC DNAwas infectious following in vivo delivery,
infectious virus was readily produced following in vitro
delivery by transfection, with approximately 105 pfu of
virus being produced following transfection of 1 Ag of
BAC DNA. Since it is difficult to determine the amount
of virus produced by in vivo delivery of HSV2-BAC DNA
and it is not clear that in vivo delivery of DNA is as efficient
as in vitro transfection, we compared in vivo delivery of
1 Ag of BAC DNA to two concentrations of HSV2-BAC
virus, 5  104 and 5  102 pfu. High levels of HSV-
specific IgG antibody responses were elicited by both
HSV2-BAC DNA immunization and the higher dose of
virus inoculation [5.15 and 4.07 (P = 0.016), respectively].
Similarly, good neutralizing antibody responses were pro-
duced after immunization, and the antibody isotype
responses elicited in each group were qualitatively similar.
Some caution should be observed in evaluation of the
significance of the antibody titers and neutralization titers
between the DNA- and the virus-infected animals. Clearly,
there is a dose response effect that is dependent on the
amount of live virus given for immunization (Fig. 4A), and
it is very likely that a further increase in the dose of virus
would have produced even higher levels of specific anti-
body. We also have not attempted a dose-ranging study with
the HSV2-BAC DNA. Most importantly, the results indi-
cated that HSV2-BAC DNAwas strongly immunogenic and
suggested the feasibility of virus immunization by DNA
delivery.
To assess the feasibility of DNA immunization with a
replication-defective HSV-2 BAC, the HSV-2 gD gene was
eliminated by mutagenesis of the HSV2-BAC. The gD gene
was chosen for elimination to validate the power of the BAC
mutagenesis procedure to construct nonreplicating virus
mutants. Further, deletion of an immunodominant antigen
such as gD would provide a rigorous test of the potential
immunogenicity of BAC DNA. Elimination of the essential
HSV-2 gD gene was relatively straightforward and did not
require prior construction of a complementing cell line.
However, a Vero cell line expressing the HSV-1 gD was
utilized to verify the gD-negative phenotype and to produce
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constructing cell lines expressing sufficient levels of multi-
ple complementing genes, BAC mutagenesis procedures are
therefore especially useful for mutagenesis and isolation of
viral genomes containing multiple disabling mutations.
DNA immunization with a replication-defective HSV-1
BAC has been reported previously (Suter et al., 1999). In that
study, a packaging-defective HSV-1 genome cloned as a
BAC (fHSV pac) (Saeki et al., 1998) induced a broad
immune response that protected immunized mice from
intracerebral challenge. An HSV-1 antibody response was
detected after one gene gun immunization of BAC DNA, and
increased after a second and third immunization; neutralizing
antibody was detected after two immunizations. Like our
HSV2 gD-BAC, the fHSV pac should replicate and produce
noninfectious virus-like particles. The fHSV pac on the other
hand should express the entire complement of HSV-1 genes
including HSV-1 gD. It is somewhat difficult to compare the
relative protective capacities and immune responses elicited
by the packaging defective HSV-1 BAC and the replication-
competent and -incompetent HSV-2 BACs described in our
study. In the HSV-1 study, BAC immunization is compared
to an HSV-1 gH-deletion virus. In our HSV-2 study, we have
compared HSV-2 BAC DNA immunization to replicating
virus generated from the BAC clone and to an HSV-2 gD-
deletion BAC. Nevertheless, the fact that fundamentally
different HSV BACs can elicit protective immune responses
in at least some animal models strongly suggests the feasi-
bility of BAC DNA immunization.
While gene gun inoculation of animals with HSV2 gD-
BAC DNA elicited an HSV-specific antibody and neutraliz-
ing antibody response that was lower than the corresponding
HSV2-BAC DNA response, animals were still protected
against a lethal virus challenge. These results were not com-
pletely surprising. Immunization with HSV, purified gD
glycoprotein, or gD DNA produces a strong humoral
response to gD and is protective. Nonetheless, the immune
response to HSV is complex and directed to many viral
antigens in addition to gD. Many other HSV glycoproteins
elicit an antibody response that is protective in various
animal challenge models. More importantly, the ability to
systematically and sequentially eliminate individual and
multiple HSV-2 antigens using BAC technology provides
a powerful tool for dissecting the immune response to
HSV-2.
The advantages of cloning large viral genomes as BACs
are numerous. Perhaps the most exciting is the ability to
construct recombinant genomes that would be difficult
under other circumstances, as described above and previ-
ously for other herpesviruses (Brune et al., 2000). The
possibility that viral vaccines could be delivered as BAC
DNA opens up other interesting possibilities that could
facilitate vaccine development. If delivery of live virus via
BAC DNA proved to be practical, technical problems
associated with poor growth and yields of mutated virus
even on a complementing cell line could be circumvented.Of course, issues associated with the large-scale production
of BAC DNAwould have to be addressed. Further, there are
obvious advantages conferred by maintenance of novel viral
vaccine stocks as BAC DNA and bacterial stocks containing
the recombinant BAC. In such cases, new vaccine stocks
could be re-derived as required to address emerging con-
cerns regarding the virus seed history or the material used
for virus stock preparation. The ability to rapidly construct
novel HSV-2 genomes using BAC technology as described
here should facilitate the development and evaluation of
candidate HSV-2 vaccine candidates.Materials and methods
Cells and viruses
Vero cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA) and maintained
in Dulbecco’s Minimal Essential Medium (DMEM) supple-
mented with 10% fetal bovine serum (FBS), 2 mM Gluta-
max-1, and 0.05 mg/ml Gentamicin (Gibco-BRL, Grand
Island, NY). VD60 cells, a Vero cell line that expresses the
HSV-1 gD (Ligas and Johnson, 1988), were a gift from Dr.
David C. Johnson, Department of Molecular Microbiology
and Immunology, Oregon Health Sciences University.
These cells were maintained as suggested in Eagle MEM
lacking histidine (MEM  his) supplemented with 1 mM
histidinol (Sigma Chemical Co., St. Louis) and 5% FBS.
Before infection, VD60 cells were passaged two times in
DMEM containing 10% FBS. The strain MS of herpes
simplex virus 2, originally isolated from the brain of a
patient with multiple sclerosis, was obtained from the
ATCC, plaque-purified, propagated, and titrated in Vero
cells. Viral DNA was isolated as described elsewhere
(Denniston et al., 1981).
Construction of plasmids
To construct the insertion plasmid, pSP72tk2-BeloBAC,
we first cloned two regions of the HSV-2 thymidine kinase
gene into the cloning vector pSP72 (Promega Corporation,
Madison, WI). The two tk fragments, flank-1 and flank-2,
were made by PCR amplification from HSV-2 genomic
DNA template. Primer sequences were designed based on
the published data for HSV-2 strain HG52 (Dolan et al.,
1998). Flank-1 consisted of the 3V-most 585 bp of the tk
coding sequence plus an additional 1.167 kb of downstream
sequence and was amplified by the primers, tk-a
(5VATCTCGAGCCCCATGAAGCCCTTCCCG; coordi-
nates 45706–45732) and tk-b (5VGGAAGCTTGACCCC
CCAGGCCGTGTTG; coordinates 47460–47434), incor-
porating an XhoI and a HindIII site (in bold), respectively, at
the 5Vend of each primer. The sequence of flank-2 consisted
of the 5V547 bp of the tk coding sequence, plus an additional
1.176 kb of upstream flanking sequence. Flank-2 was
C.A. Meseda et al. / Virology 318 (2004) 420–428 427amplified with the primers tk-c (5VGTCAAGCTTCCCAT
GAGGTACCGCGCG; coordinates 47450–47476) and tk-d
(5VGTCTAGAGGGGGATGTTGAACACGGGCA; coordi-
nates 49176–49149), incorporating a HindIII and a XbaI
(in bold) site, respectively, at the 5Vend of the primers. This
cloning strategy resulted in the intermediate insertion plas-
mid, pSP72-tk2, which contains approximately 3.47 kb of
the tk gene locus and flanking HSV-2 sequences, with a
unique HindIII restriction site near the middle of the tk
coding region. The HindIII restriction site at this position
allowed easy insertion of the linearized 7.5-kb BeloBAC11
vector (Research Genetics, Huntsville, AL) to generate
pSP72tk2-BeloBAC. The authenticity of all constructs was
confirmed by sequencing in an ABI-377 DNA sequencer
(Applied Biosystems, Foster City, CA). PCR products were
initially cloned using the Zero Blunt Topo PCR cloning kit
(Invitrogen, Carlsbad, CA). Routine isolation and purifica-
tion of plasmids was performed using Qiagen plasmid
purification kits and protocols described by the manufac-
turers (Qiagen Inc., Valencia, CA).
To construct the glycoprotein D (gD)-deletion replace-
ment vector, we amplified two regions of the HSV-2 gD
gene by PCR and cloned these fragments into the cloning
vector pGEM3 (Promega). One fragment consisted of the
2016 bp immediately upstream of the first ATG of the gD-
coding sequence; the second fragment consisted of the 2106
bp immediately downstream from the end of the gD-coding
sequence. This approximately 4-kb region with gD-coding
sequences deleted was transferred to the Gateway entry
vector pENTR1A (Invitrogen). The resulting plasmid con-
struction, pENTR-1A-gD5678, was used to transfer the gD
region into a BAC gene replacement vector, pKO5.2-C.1, to
yield pKO5.2-C.1-gD5678 for BAC mutagenesis. The vec-
tor pKO5.2-C.1 is a derivative of the previously described
gene replacement vectors pKO5 and pKO5.1 (Horsburgh et
al., 1999a, 1999b), modified for use as a Gateway destina-
tion vector by the insertion of a gene cassette containing
attR recombination sites into the multiple cloning region
(manuscript in preparation).
BAC mutagenesis
Mutagenesis of the HSV2-BAC was essentially as
described previously (Horsburgh et al., 1999a, 1999b).
Briefly, RR1 electrocompetent cells were transformed with
HSV2-BAC DNA and selected for chloramphenicol resis-
tance. The electroporation conditions employed 0.1-cm
cuvets (BTX, San Diego, CA) and a 1.8-kV setting on a
Transporator Plus (BTX). Clones were confirmed by PCR
with three independent HSV-2 specific primer pairs and a
primer pair amplifying a fragment in the chloramphenicol
acetyltransferase (cat) gene. Electrocompetent RR1 cells
harboring the HSV-2 BAC were prepared as previously
described (Ausubel et al., 1987). Electrocompetent RR1
cells containing the HSV2-BAC were electroporated with
10 ng of pKO5.2-C.1-gD5678 DNA, and plated ontochloramphenicol/zeocin (Cam/Zeo) plates in serial dilu-
tions at 30 jC. The following day, multiple colonies were
picked into 1 ml of LB broth and plated in serial dilutions
onto Cam/Zeo plates at 43 jC. Colonies at 43 jC were
analyzed by picking several into 1 ml LB each and
immediately plating out 10 and 100 Al onto sucrose/
chloramphenicol (Suc/Cam) plates at 30 jC. Approximate-
ly 10 colonies from each plate, representing an original 43
jC colony, were transferred to grids on Suc/Zeo and Cam
LB plates at 30 jC. Colonies which grew on Cam plates
but not on Zeo/Suc, (i.e., Cam+, Zeo/Suc ) were picked
into 100 Al of 10 mM Tris pH 8.0 for colony PCR using
HSV-2 specific primers along with a primer pair flanking
the gD-coding region. Positive colonies were streaked out
onto Cam plates and grown at 37 jC. Clones were grown
in Cam-LB media for glycerol stocks and subsequent large
preparations of HSV2 gD-BAC DNA using the Large
Construct kit (Qiagen Inc.).
Animals and immunization
BALB/cByJ mice were purchased from Jackson Labo-
ratories, Bar Harbor, ME, and housed in cages at a core
facility in the Center for Biologics Evaluation and Re-
search (CBER), Bethesda, MD. Sterile food and drinking
water were supplied ad libitum, and general care and
handling procedures were performed according to a proto-
col approved by the Animal Care and Use Committee of
CBER/FDA. Mice were used in experiments at between
8 and 12 weeks of age, and age-matched within an
experiment. DNA immunizations by gene gun inoculation
and HSV-2 intraperitoneal challenges were performed as
previously described (Meseda et al., 2002). Live virus
immunizations were by intradermal injection at the base
of the tail.
Antibody and neutralizing antibody determination
Detection of antibody to HSV glycoprotein by ELISA
(Pachl et al., 1987) was performed as previously described
(Meseda et al., 2002; Nass et al., 1998), using a mixture of
HSV-2 glycoproteins or an inactivated HSV-2-infected cell
extract. Endpoint titer was defined as the highest dilution of
serum that gave an A405 value that was 2-fold greater than
that of the matched dilution of normal prebleed mouse
serum and was also greater than 0.050. Neutralizing anti-
body assays were performed using 96-well plates containing
5  104 Vero cells and 5  103 pfu of HSV-2 per well as
previously described (Meseda et al., 2002; Nass et al.,
1998). Sera were assayed from individual mice within each
group tested (n = 5).
Statistical analysis
Significant differences in antibody titers between groups,
defined as P < 0.05, were analyzed using an unpaired, two-
C.A. Meseda et al. / Virology 318 (2004) 420–428428tailed Student’s t test with InStat software (GraphPad
Software). Significant differences in survival between chal-
lenged groups of mice were analyzed using Fisher’s exact
test with InStat software.Acknowledgments
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